triphenyl(carbethoxymethyl)phosphonium bromide | 4083-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: triphenyl(carbethoxymethyl)phosphonium bromide
• 英文别名: ethyl 2-(bromotriphenylphosphoranyl)acetate；carboethoxytriphenylphosphoniumbromide；Ethyl 2-(bromotriphenyl-l5-phosphanyl)acetate；ethyl 2-[bromo(triphenyl)-λ5-phosphanyl]acetate
• CAS: 4083-85-6
• 化学式: C₂₂H₂₂BrO₂P
• 分子量: 429.293
• InChiKey: UYMZZYLECILSGL-UHFFFAOYSA-N

物化性质

• 熔点：
  152-153 °C

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  triphenyl(carbethoxymethyl)phosphonium bromide 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 0.5h， 生成 乙氧甲酰基亚甲基三苯基膦
  参考文献：
  名称：

  Cappon, J. J.; Baart, J.; Walle, G. A. M. van der, Recueil des Travaux Chimiques des Pays-Bas, 1991, vol. 110, # 5, p. 158 - 166

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1-dibromo-tetrahydro-1λ⁴-thiophene 、 乙氧甲酰基亚甲基三苯基膦 以100%的产率得到
  参考文献：
  名称：

  MAGDESIEVA N. N.; KYANDZHETSIAN R. A., ZH. ORG. XIMII, 1979, 15, HO 11, 2396-2402

  摘要：

  DOI：

文献信息

• Amino acid amides of piperic acid (PA) and 4-ethylpiperic acid (EPA) as NorA efflux pump inhibitors of Staphylococcus aureus
  作者：Naiem Ahmad Wani、Samsher Singh、Saleem Farooq、Sudha Shankar、Surrinder Koul、Inshad Ali Khan、Rajkishor Rai

  DOI：10.1016/j.bmcl.2016.07.062

  日期：2016.9

  A total of eighteen piperic acid (PA) and 4-ethylpiperic acid (EPA) amides (C1-C18) with α-, β- and γ-amino acids were synthesized, characterized and evaluated for their efflux pump inhibitory activity against ciprofloxacin resistant Staphylococcus aureus. The amides were screened against NorA overexpressing S. aureus SA-1199B and wild type S. aureus SA-1199 using ethidium bromide as NorA efflux pump

  合成了总共18种带有α-，β-和γ-氨基酸的哌酸（PA）和4-乙基哌酸（EPA）酰胺（C1-C18），表征并评估了其对耐环丙沙星葡萄球菌的外排泵抑制活性金黄色的。使用溴化乙锭作为NorA外排泵底物，针对过表达NorA的过表达金黄色葡萄球菌SA-1199B和野生型金黄色葡萄球菌SA-1199筛选酰胺。发现EPI C6最有效，环丙沙星的MIC降低了16倍，其次是C18，MIC降低了4倍。溴化乙锭的流出抑制和蓄积分析证明了这些化合物是NorA抑制剂。
• Study of IspH, a Key Enzyme in the Methylerythritol Phosphate Pathway Using Fluoro-Substituted Substrate Analogues
  作者：Youli Xiao、Wei-chen Chang、Hung-wen Liu、Pinghua Liu

  DOI：10.1021/ol202559r

  日期：2011.11.4

  IspH, a [4Fe-4S]-cluster-containing enzyme, catalyzes the reductive dehydroxylation of 4-hydroxy-3-methyl-butenyl diphosphate (HMBPP) to isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) in the methylerythritol phosphate pathway. Studies of IspH using fluoro-substituted substrate analogues to dissect the contributions of several factors to IspH catalysis, including the coordination

  IspH 是一种含 [4Fe-4S] 簇的酶，可在甲基赤藓糖醇磷酸酯途径中催化 4-羟基-3-甲基-丁烯基二磷酸 (HMBPP) 还原脱羟基为异戊烯二磷酸 (IPP) 和二甲基烯丙基二磷酸 (DMAPP)。使用氟取代底物类似物对 IspH 进行研究，以剖析几个因素对 IspH 催化的贡献，包括 HMBPP C 4 –OH 基团与铁硫簇的配位、活性位点中的 H 键网络以及报道了基板的电子特性。
• Prophylactic/Therapeutic Agent for Diabetes
  申请人：Cho Nobuo

  公开号：US20090264650A1

  公开（公告）日：2009-10-22

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种11β-羟基类固醇脱氢酶1抑制剂，其包括由式（1）表示的化合物，其中每个符号如描述中所定义的，或其盐或前药。本发明的11β-羟基类固醇脱氢酶1抑制剂具有优异的活性，可用作药物剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖症、异常脂质代谢、高血压等的药剂。
• PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1864971A1

  公开（公告）日：2007-12-12

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种 11β-羟基类固醇脱氢酶 1 抑制剂，由式（1）代表的化合物组成： 其中各符号如说明中所定义，或其盐，或其原药。本发明的11β-羟类固醇脱氢酶1抑制剂具有优异的活性，可作为药物制剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖、脂代谢异常、高血压等疾病的药物。
• Strong Bicyclic Guanidine Base-Promoted Wittig and Horner−Wadsworth−Emmons Reactions
  作者：Daniele Simoni、Marcello Rossi、Riccardo Rondanin、Angelica Mazzali、Riccardo Baruchello、Cinzia Malagutti、Marinella Roberti、Francesco Paolo Invidiata

  DOI：10.1021/ol0001665

  日期：2000.11.1

  [GRAPHICS]A convenient procedure to effect the Wittig and Horner-Wadsworth-Emmons reactions employs guanidine TBD and MTBD as base-promoters; mild reaction conditions, high efficiency, and facile isolation of the final products make the present methodology, at least in some cases, a practical alternative to known procedures.